MeSH D000326 - adrenoleukodystrophy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D038901:X-linked mental retardation
0 Companies
0 Drugs
Success rate
D018901:Peroxisomal disorders
0 Companies
0 Drugs
Success rate
D020279:Hereditary central nervous system demyelinating diseases
0 Companies
0 Drugs
Success rate
D020739:Metabolic brain diseases inborn
0 Companies
0 Drugs
Success rate
D000309:Adrenal insufficiency
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| bluebird bio | Elivaldogene autotemcel | Skysona | 2022-09-16 | $9.896 M | Q1/23-Q2/24 |
Clinical Trials
Historical Success Rate
Phase 1
25%1/4
Phase 2
30%6/20
Phase 3
25%2/8
Approved: 1Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use